Citius Oncology shares jump 11.16% intraday as AI platform deployment and LYMPHIR launch preparations boost optimism.

Citius Oncology surged 11.16% intraday following the announcement that it deployed an AI platform to enhance the performance of its commercial team ahead of the LYMPHIR launch. The move signals a strategic step to optimize commercial operations for its key product, potentially accelerating market adoption and revenue growth. The news, released on August 22, 2025, aligns with the company’s ongoing efforts to strengthen commercial infrastructure, including recent expansions of its LYMPHIR distribution network and Nasdaq compliance. With LYMPHIR anticipated to launch in 2025 and supported by a unique J-Code from CMS, the AI initiative is viewed as a catalyst for improved sales execution and market penetration.